Andrew Hollman Meyer Sells 3,334 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) Stock

Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) insider Andrew Hollman Meyer sold 3,334 shares of the company's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $42.29, for a total value of $140,994.86. Following the transaction, the insider now directly owns 82,139 shares of the company's stock, valued at approximately $3,473,658.31. This represents a 3.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Andrew Hollman Meyer also recently made the following trade(s):

• On Thursday, January 2nd, Andrew Hollman Meyer sold 13,334 shares of Janux Therapeutics stock. The shares were sold at an average price of $54.88, for a total value of $731,769.92.

Janux Therapeutics Stock Down 3.2 %

Shares of JANX traded down $1.31 on Friday, reaching $39.37. The stock had a trading volume of 795,365 shares, compared to its average volume of 1,007,999. The firm has a market capitalization of $2.07 billion, a PE ratio of -33.65 and a beta of 3.16. Janux Therapeutics, Inc. has a twelve month low of $7.81 and a twelve month high of $71.71. The firm has a 50-day moving average of $51.07 and a 200 day moving average of $48.30.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The company had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The business's quarterly revenue was down 82.6% on a year-over-year basis. On average, sell-side analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Institutional Trading of Janux Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in JANX. Arizona State Retirement System lifted its holdings in Janux Therapeutics by 95.4% in the 4th quarter. Arizona State Retirement System now owns 11,670 shares of the company's stock valued at $625,000 after purchasing an additional 5,697 shares in the last quarter. Proficio Capital Partners LLC acquired a new position in shares of Janux Therapeutics during the 4th quarter valued at about $1,353,000. Victory Capital Management Inc. lifted its holdings in shares of Janux Therapeutics by 715.0% during the 4th quarter. Victory Capital Management Inc. now owns 242,409 shares of the company's stock worth $12,979,000 after acquiring an additional 212,664 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Janux Therapeutics by 16.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 273,135 shares of the company's stock worth $14,624,000 after acquiring an additional 38,944 shares during the last quarter. Finally, HealthInvest Partners AB purchased a new stake in Janux Therapeutics in the fourth quarter valued at approximately $2,078,000. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently weighed in on JANX. Cantor Fitzgerald reissued an "overweight" rating and issued a $200.00 price target on shares of Janux Therapeutics in a research report on Wednesday, December 11th. Lifesci Capital raised Janux Therapeutics to a "strong-buy" rating in a research report on Friday, December 27th. UBS Group initiated coverage on Janux Therapeutics in a research report on Thursday, October 24th. They set a "buy" rating and a $69.00 price target on the stock. BTIG Research raised their price objective on shares of Janux Therapeutics from $82.00 to $100.00 and gave the stock a "buy" rating in a research report on Tuesday, December 3rd. Finally, Stifel Nicolaus upped their price target on Janux Therapeutics from $70.00 to $115.00 and gave the stock a "buy" rating in a research note on Tuesday, December 3rd. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $89.90.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.